跳至主要内容
临床试验/NCT06668922
NCT06668922招募中不适用

Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome (IBS) and Control Volunteers: Diet Challenge

University of California, Los Angeles1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2024年11月28日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
72
试验地点
1
主要终点
Total fecal bile acids

研究概览

简要总结

The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms. Primary aims include: (a) identifying GI microbiome signatures in IBS subtypes (IBS-C and IBS-D) and matched controls, and test if microbiome signatures in these groups correlate with fecal SCFAs and bacterial fermentation of an indigestible carbohydrate (inulin) after a dietary challenge (fecal inulin), and (b) determining if GI microbiome signatures in IBS subtypes and controls correlate with fecal BAs or markers of SCFA production (fecal SCFAs or inulin) and test if BAs correlate with fecal SCFAs or inulin.

The target population is adults ages 18-65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis.

详细描述

During the study:

Screening/Visit 1

  • Participants will be asked to read and sign this informed consent after all questions about the study have been answered to satisfaction.
  • This is a screening visit, and we may determine that a participant is ineligible to continue to participate in the study.
  • The study team will collect medication and medical history.
  • A physical exam will be performed by the physician. Vital signs and body measurements will be collected.
  • Participants will be provided with a take-home lasagna meal (vegetarian and non-vegetarian option) and dessert.
  • Participants will receive a stool collection kit and instructions for the collection, storage, and transportation of stool.
  • Instructions will be provided for a low fiber, high fat diet for Days 2-4.
  • Participants will be asked to complete diet recall using the ASA24 and a bowel pattern diary to record bowel symptoms over the course of the study.
  • IBS participants will complete the irritable bowel syndrome severity scoring system questionnaires (IBS-SSS).

Day 2-4 (at home):

  • Participants will record stool symptoms and patterns in a diary daily.
  • Participants will be instructed to consume a low fiber diet (maximum one piece of fruit and 100 g of vegetables a day, and white flour instead of whole grain products), avoid alcohol, and start a 4-day 100 g fat diet.
  • On the evening before Day 5, participants will be instructed to collect a stool sample at home and return during Visit 2.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Age 18-75
  • •Individuals with irritable bowel syndrome (IBS)
  • •Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms
  • •No dietary restrictions other than vegetarian

排除标准

  • •Inflammatory bowel disease, celiac disease, or certain types of abdominal cancer, as well as those with thyroid or liver issues
  • •Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal
  • •Use of any prescription, over the counter, or herbal medications known to affect gastrointestinal function or study interpretation, such as opioids, inflammatory drugs or certain antidepressants, within 6 months prior to study participation for healthy volunteers, or within 2 days of study participation for participants with IBS.
  • •An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month.
  • •Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed.
  • •Use of Ozempic and Ozempic-type medications
  • •Pregnant or breastfeeding women
  • •Antibiotic use within 3 months of study participation
  • •Use of prebiotics or probiotics within the 2 weeks before the study initiation
  • •Regular tobacco use within the past 6 months

研究组 & 干预措施

Irritable Bowel Syndrome Patients with Constipation (IBS-C)

Experimental

Patients with irritable bowel syndrome (IBS) with constipation, ages 18-65 years fulfilling Rome IV criteria for IBS.

干预措施: Inulin (Dietary Supplement)

Irritable Bowel Syndrome Patients with Diarrhea (IBS-D)

Experimental

Patients with irritable bowel syndrome (IBS) with diarrhea, ages 18-65 years fulfilling Rome IV criteria for IBS.

干预措施: Inulin (Dietary Supplement)

Healthy volunteers

Experimental

Adults ages 18-65 years with no prior history of gastrointestinal diseases or symptoms.

干预措施: Inulin (Dietary Supplement)

结局指标

主要结局

Total fecal bile acids

时间窗: 48 hours

Stool samples will be collected over 2 days for measurement of fecal bile acids (µmol/48h) by high performance liquid chromatography-mass spectometry.

Total fecal short chain fatty acids

时间窗: 48 hours

Stool samples will be collected for measurement of measurement of short chain fatty acids (µg/mg) by liquid chromatography-mass spectrometry

Individual fecal short chain fatty acids

时间窗: 48 hours

Stool samples will be collected for measurement of measurement of short chain fatty acids (µg/mg) by liquid chromatography-mass spectrometry

Fecal microbial population

时间窗: 48 hours

Stool samples will be be collected from participants for nucleic acid extraction, 16S allele PCR and sequencing to measure microbial communities and profiles of specimens

Fecal inulin

时间窗: 48 hours

Fecal inulin content will be measured using short acid hydrolysis and high-performance liquid chromatography

次要结局

  • Stool characteristics(4 days)
  • Percent primary fecal bile acids(48 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrea S. Shin, MD

Associate Professor

University of California, Los Angeles

研究点 (1)

Loading locations...

相似试验